Appendix 4C and Quarterly Activities Report - March 2026
Filed with ASX · · 8 pages · English
Imagion Biosystems Ltd. on 6ix
Story so far
Earlier from Imagion Biosystems
- FY25 Appendix 4E and Annual Report
- Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
- IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
- Appendix 4C and Quarterly Activities Report - December 2025
- Mercer Convertible Securities Conversion and Amendment
Later from Imagion Biosystems
- Imagion Biosystems Receives IND Clearance from US FDA
- Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
- IBX Secures Firm Commitments for $3.75m for Clinical Trial
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- Appendix 4C and Quarterly Activities Report - June 2026
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems